A rapid immunohistochemical primary screening assay for hybridomas

Area of Science:

• Immunology
• Biotechnology
• Neuroscience

Background:

• Hybridoma technology produces monoclonal antibodies (mAbs) requiring high-throughput screening.
• Selecting mAbs for specific applications like immunohistochemistry necessitates tailored screening methods.
• Current methods for primary mAb screening are often time-consuming and limited in capacity.

Purpose of the Study:

• To develop a rapid, single-step micromethod for the primary screening of monoclonal antibodies.
• To enable efficient selection of antibodies suitable for immunohistochemistry.
• To increase the throughput of antibody screening compared to classical methods.

Main Methods:

• Developed a novel micromethod combining 96-well plate assay capacity with microscopic immunohistochemical specificity.
• Applied the method for primary screening of hybridoma culture supernatants.
• Validated the system by selecting mAbs targeting Alzheimer's disease pathology and phosphoprotein pp32.

Main Results:

• The micromethod allows for the processing of hundreds of culture supernatants in a single assay round.
• Successfully selected monoclonal antibodies specific for Alzheimer's disease-related neurofibrillary pathology.
• Identified monoclonal antibodies recognizing phosphoprotein pp32 in rat brain sections.

Conclusions:

• The developed micromethod offers a rapid and efficient approach for primary screening of monoclonal antibodies.
• This technique significantly enhances the capacity for selecting antibodies for immunohistochemistry.
• The method is effective for identifying disease-specific antibodies in neurological research.